verified COP 23,7 · D1 • database Scopus / SJR & Web of Science indexed

United Kingdom · Elsevier Ltd

workspace_premium D1 Top 10% — Hematology visibility_off Single blind Peer Review lock_open Open Access

Annals of Oncology

Annals of Oncology is a journal indexed in SJR in Medicine (miscellaneous) and Hematology with an H index of 311. It is an CC BY Journal with a Single blind Peer Review review system The scope of the journal is focused on Cancer, Oncology, Systemic anticancer therapy, Molecular pathology. It has a COP Index of 23,7 (best band D1). It is published in English. It has a COP Index of 23,7.

Annals of Oncology focuses its scope in these topics and keywords: cancer, patients, advanced, phase, lung, metastatic, clinical, trial, ii, treatment, ...

ISSN: 0923-7534

Publisher: Elsevier Ltd

Category: Medicine (miscellaneous)

Indexation: verifiedScopus / SJR verifiedWeb of Science

open_in_new Visit publisher site menu_book Author guidelines

schedule CountryOfPapers database fields

COP Index trending_up

23,7 D1 Top 10%

3 of 119 journals in Hematology

H-index · SJR 311 · 19,072

Acceptance rate pie_chart

18% Selective

Source Acceptance_Rate

Time to publication hourglass_top

NPD

Field NPD

Publication cost (APC) payments

NPD Open Access

Non-OA path 0 €

Metrics

Scimago and CountryOfPapers database fields

Scopus / SJR Web of Science

COP Index

23,7

D1 Top 10%

SJR Impact

19,072

H-index

311

Docs (year)

167

Docs 3y

546

Total refs

4859

Cites 3y

11555

Citable 3y

301

Cites/Doc 2y

22.61

Ref/Doc

29.1

Immediate OA

—

Embargoed OA

NPD

Non OA / Submission

0 €

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

BEACOPP therapeutic regimen for patients with Hodgkin's disease and HIV infection

Treatment-related premature ovarian failure as a long-term complication after Hodgkin's lymphoma

Dealing with metastatic breast cancer in elderly women: results from a French study on a large cohort carried out by the 'Observatory on Elderly Patients'

Crossover is not associated with faster trial accrual

Conko-006: a Randomized Double-Blinded Phase Iib-Study of Adjuvant Therapy with Gemcitabine + Sorafenib/Placebo for Patients with R1-Resection of Pancreatic Cancer

Comparing long-term toxicity and efficacy of combined modality treatment including extended- or involved-field radiotherapy in early-stage Hodgkin's lymphoma

Communication skills training in oncology: a position paper based on a consensus meeting among European experts in 2009

Coming into focus: the nonovarian origins of ovarian cancer

Circulating cell-free DNA as predictor of treatment failure after neoadjuvant chemoradiotherapy before surgery in patients with locally advanced rectal cancer: is it ready for primetime?

Circulating cell-free DNA as predictor of treatment failure after neoadjuvant chemo-radiotherapy before surgery in patients with locally advanced rectal cancer

Centralised multidisciplinary re-evaluation of diagnostic procedures in patients with newly diagnosed Hodgkin lymphoma

Best choice of central venous insertion site for the prevention of catheter-related complications in adult patients who need cancer therapy: a randomized trial

SHOW MORE ARTICLES

BEACOPP: An intensified chemotherapy regimen in advanced Hodgkin's disease

A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)

Autologous stem cell transplantation for primary refractory Hodgkin's disease: results and clinical variables affecting outcome

Assessment of cardiotoxicity (CT) associated with doxorubicin (dox) in patients (pts) with advanced soft tissue sarcoma (STS) in a phase III randomized trial

Aromatase inhibitors and the risk of colorectal cancer in postmenopausal women with breast cancer

Are liquid biopsies a surrogate for tissue EGFR testing?

Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study

An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma

An analysis of prognostic factors in stage III and IV Hodgkin's disease treated at a single centre with MVPP

Adjuvant sunitinib for high-risk-resected renal cell carcinoma: a meta-analysis of ASSURE and S-TRAC trials

A population-based cohort study on early-stage Hodgkin lymphoma treated with radiotherapy alone: with special reference to older patients

A polymorphic MYC response element in KBTBD11 influences colorectal cancer risk, especially in interaction with an MYC-regulated SNP rs6983267

FAQs

Annals of Oncology has a COP Index of 23,7 (D1), ranked 3 of 119 in Hematology. SJR: 19,072.

Immediate OA APC is not available (NPD). Non-OA / submission fee is 0 EUR.

The acceptance rate recorded for Annals of Oncology is 18%.

Annals of Oncology

Metrics

Name good journals. Call out predatory ones.

Researcher reviews

Best articles by citations

FAQs

What is the COP Index of Annals of Oncology?

What is the APC / publication cost?

What is the acceptance rate?